Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A Single Dose Study to Assess the Biocomparison of MK-8669 in Subjects
To evaluate the whole blood pharmacokinetics and comparative bioavailability (AUC0-∞, Cmax, Tmax and apparent t1/2) of 2 new granule formulations of ridaforolimus compared to the provisional market 10...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
An Observational follow-up study to Protocol 018
To collect and assess safety information for the double-blinded treatment period ending 5 years post-randomization regarding deaths, SAEs, adverse events requiring adjudication, and skin ECIs in subje...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
MK-518B Food Effect Study
Assess the effect of a high-fat meal on the in vivo performance of Raltegravir/lamivudine (MK-0518B) 300 mg/150 mg Fixed-Dose Combination (FDC) tablets from Merck Sharp & Dohme Corp., a subsidiary of ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy
To compare the overall survival associated with vorinostat plus best supportive care versus that associated with placebo plus best supportive care for the treatment of patients with advanced malignant...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
For Treatment Augmentation in Patients with Major Depressive Disorder
): (1) To evaluate the efficacy of MK-6096 in comparison with placebo as treatment augmentation for patients with MDD, based on change from baseline to week 6 in MADRS total score. (2) To assess the ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Study investigating a new medicine - MK-1439 in patients diagnosed with HIV-1 without previous treatment for this disease. The study has 2 parts and neither the doctor or patient will know the treatment group. All the patients will be treated with Truvada, some of the patients will be treated in addition with MK-1439, while the others will be treated in addition with Efavirenz. Estudio de búsqueda de un nuevo medicamento -MK-1439 en pacientes infectados por el VIH-1 sin tratamiento previo de esta enfermedad. El estudio tiene consta de dos partes, ni el doctor ni el paciente conocerán el grupo de tratamiento. Todos los pacientes serán tratados con TRUVADA, algunos de ellos serán tratados adicionalmente con MK-1439, mientras que otros lo serán con Efavirenz
Part I 1. Objective: Evaluate the safety and tolerability of MK-1439, at the studied doses, compared to efavirenz, each in combination with TRUVADA® for 24 weeks. 2. Objective: Evaluate the antiretrov...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Study to Evaluate The Efficacy and Safety of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformin Monotherapy
The primary objectives and hypotheses of the trial are: 1. Objective: At Week 26, to assess the effect on HbA1c of 15 mg ertugliflozin as compared with placebo. Hypothesis: At Week 26, the mean re...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A worldwide placebo-controlled study to evaluate the additional lipid benefits of extended release (ER) niacin/laropiprant when taken with current lipid-modifying therapy in individuals with abnormal lipids
To evaluate the efficacy of ERN/LRPT 2 g relative to placebo on plasma LDL-C at Week 12 of treatment.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
The effect and long-term safety of MK-0887A in children with asthma
Primary Efficacy Objective: To demonstrate the efficacy of MF/F 100/10 mcg twice daily, compared with MF 100 mcg twice daily, by evaluating lung function during the first 12 weeks of double-blind tre...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., N.J., USA
MAJ Il y a 5 ans
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled with Simvastatin 20 mg or Atorvastatin 10 mg: A Comparison of Switching to a Combination Tablet Ezetimibe/Simvastatin (10mg/20mg) Versus Switching to Rosuvastatin 10mg or Doubling the Statin Dose
In patients with cardiovascular disease (CVD) and diabetes mellitus treated with simvastatin 20 mg or atorvastatin 10 mg with LDL-Cholesterol blood level (LDL-C) ≥70 mg/dl (1.81 mmol/L) and ≤160 mg/dl...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
3
4
5
6
7
8
9
10
11
12
Suivant